(Q39821890)

14 September 2017

title

Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies (English)

1 reference

14 September 2017

Gadi Gazit Bornstein

1

1 reference

14 September 2017

Christophe Quéva

2

1 reference

14 September 2017

Mohammad Tabrizi

3

1 reference

14 September 2017

Anne van Abbema

4

1 reference

14 September 2017

Carlos Chavez

5

1 reference

14 September 2017

Ping Wang

6

1 reference

14 September 2017

Orit Foord

7

1 reference

14 September 2017

Kiran Ahluwalia

8

1 reference

14 September 2017

Naomi Laing

9

1 reference

14 September 2017

Sandhya Raja

10

1 reference

14 September 2017

Shenghua Wen

11

1 reference

14 September 2017

Larry L Green

12

1 reference

14 September 2017

Xiaodong Yang

13

1 reference

14 September 2017

Carl Webster

14

1 reference

14 September 2017

Ross Stewart

15

1 reference

14 September 2017

David Blakey

16

1 reference

14 September 2017

publication date

21 July 2009

1 reference

Investigational New Drugs

14 September 2017

published in

1 reference

14 September 2017

volume

28

1 reference

14 September 2017

issue

5

1 reference

14 September 2017

page(s)

561-574

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-009-9291-z

14 September 2017

exact match

0 references

cites work

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-009-9291-Z

Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma

21 January 2018

1 reference

12 December 2020

Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma

1 reference

12 December 2020

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

12 December 2020

Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary struc

1 reference

12 December 2020

Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects

1 reference

12 December 2020

Characterization of a human B lymphocyte-specific antigen.

1 reference

12 December 2020

Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice

1 reference

12 December 2020

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

12 December 2020

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

1 reference

12 December 2020

Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys

1 reference

12 December 2020

Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1)

1 reference

12 December 2020

Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix

1 reference

12 December 2020

Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys

1 reference

12 December 2020

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis

1 reference

12 December 2020

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

1 reference

12 December 2020

The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice

1 reference

12 December 2020

B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation

1 reference

12 December 2020

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

1 reference

12 December 2020

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

1 reference

12 December 2020

CD20: a gene in search of a function.

1 reference

12 December 2020

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

1 reference

12 December 2020

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

1 reference

12 December 2020

Flow cytometric assay for determination of FcgammaRIIIA-158 V/F polymorphism

1 reference

12 December 2020

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

1 reference

12 December 2020

Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma

1 reference

12 December 2020

Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells

1 reference

12 December 2020

CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts.

1 reference

12 December 2020

Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.

1 reference

12 December 2020

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

1 reference

12 December 2020

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

1 reference

12 December 2020

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

12 December 2020

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

12 December 2020

Ontogeny of human hematopoietic cells: analysis utilizing monoclonal antibodies

1 reference

12 December 2020

10.1007/S10637-009-9291-Z

Identifiers

DOI

1 reference

14 September 2017

1 reference